Bridging the age gap in breast cancer: impact of omission of breast cancer surgery in older women with oestrogen receptor-positive early breast cancer on quality-of-life outcomes.
Journal
The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553
Informations de publication
Date de publication:
05 04 2021
05 04 2021
Historique:
received:
14
07
2020
accepted:
15
11
2020
pubmed:
25
3
2021
medline:
11
8
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
Primary endocrine therapy may be an alternative treatment for less fit women with oestrogen receptor (ER)-positive breast cancer. This study compared quality-of-life (QoL) outcomes in older women treated with surgery or primary endocrine therapy. This was a multicentre, prospective, observational cohort study of surgery or primary endocrine therapy in women aged over 70 years with operable breast cancer. QoL was assessed using European Organisation for Research and Treatment of cancer QoL questionnaires QLQ-C30, -BR23, and -ELD14, and the EuroQol Five Dimensions 5L score at baseline, 6 weeks, and 6, 12, 18, and 24 months. Propensity score matching was used to adjust for baseline variation in health, fitness, and tumour stage. The study recruited 3416 women (median age 77 (range 69-102) years) from 56 breast units. Of these, 2979 (87.2 per cent) had ER-positive breast cancer; 2354 women had surgery and 500 received primary endocrine therapy (125 were excluded from analysis due to inadequate data or non-standard therapy). Median follow-up was 52 months. The primary endocrine therapy group was older and less fit. Baseline QoL differed between the groups; the mean(s.d.) QLQ-C30 global health status score was 66.2(21.1) in patients who received primary endocrine therapy versus 77.1(17.8) among those who had surgery plus endocrine therapy. In the unmatched analysis, changes in QoL between 6 weeks and baseline were noted in several domains, but by 24 months most scores had returned to baseline levels. In the matched analysis, major surgery (mastectomy or axillary clearance) had a more pronounced adverse impact than primary endocrine therapy in several domains. Adverse effects on QoL are seen in the first few months after surgery, but by 24 months these have largely resolved. Women considering surgery should be informed of these effects.
Sections du résumé
BACKGROUND
Primary endocrine therapy may be an alternative treatment for less fit women with oestrogen receptor (ER)-positive breast cancer. This study compared quality-of-life (QoL) outcomes in older women treated with surgery or primary endocrine therapy.
METHODS
This was a multicentre, prospective, observational cohort study of surgery or primary endocrine therapy in women aged over 70 years with operable breast cancer. QoL was assessed using European Organisation for Research and Treatment of cancer QoL questionnaires QLQ-C30, -BR23, and -ELD14, and the EuroQol Five Dimensions 5L score at baseline, 6 weeks, and 6, 12, 18, and 24 months. Propensity score matching was used to adjust for baseline variation in health, fitness, and tumour stage.
RESULTS
The study recruited 3416 women (median age 77 (range 69-102) years) from 56 breast units. Of these, 2979 (87.2 per cent) had ER-positive breast cancer; 2354 women had surgery and 500 received primary endocrine therapy (125 were excluded from analysis due to inadequate data or non-standard therapy). Median follow-up was 52 months. The primary endocrine therapy group was older and less fit. Baseline QoL differed between the groups; the mean(s.d.) QLQ-C30 global health status score was 66.2(21.1) in patients who received primary endocrine therapy versus 77.1(17.8) among those who had surgery plus endocrine therapy. In the unmatched analysis, changes in QoL between 6 weeks and baseline were noted in several domains, but by 24 months most scores had returned to baseline levels. In the matched analysis, major surgery (mastectomy or axillary clearance) had a more pronounced adverse impact than primary endocrine therapy in several domains.
CONCLUSION
Adverse effects on QoL are seen in the first few months after surgery, but by 24 months these have largely resolved. Women considering surgery should be informed of these effects.
Identifiants
pubmed: 33760065
pii: 6184678
doi: 10.1093/bjs/znaa125
pmc: PMC10364859
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Receptors, Estrogen
0
Types de publication
Comparative Study
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
315-325Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.
Références
Psychooncology. 2008 Apr;17(4):410-6
pubmed: 17847124
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
Psychooncology. 2017 Dec;26(12):2094-2100
pubmed: 28332254
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Lancet Oncol. 2012 Apr;13(4):e148-60
pubmed: 22469125
Eur J Cancer. 2010 Aug;46(12):2242-52
pubmed: 20580993
Br J Surg. 2020 Oct;107(11):1468-1479
pubmed: 32488911
Nutr Cancer. 2005;53(1):51-6
pubmed: 16351506
Clin Oncol (R Coll Radiol). 2009 Mar;21(2):99-102
pubmed: 19200920
Br J Surg. 2018 Oct;105(11):1454-1463
pubmed: 29790154
Patient Prefer Adherence. 2019 Jan 14;13:131-143
pubmed: 30679905
Nutrition. 1996 Jan;12(1 Suppl):S15-9
pubmed: 8850213
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Md State Med J. 1965 Feb;14:61-5
pubmed: 14258950
Br J Cancer. 2018 Jul;119(1):121-129
pubmed: 29875471
JAMA Surg. 2018 Dec 1;153(12):1090-1096
pubmed: 30167636
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Br Med J (Clin Res Ed). 1982 Mar 20;284(6319):869-70
pubmed: 6802332
J Acad Nutr Diet. 2014 Jul;114(7):1088-1098
pubmed: 24462323
J Clin Oncol. 1996 Oct;14(10):2756-68
pubmed: 8874337
Breast Cancer Res Treat. 1992;22(3):207-19
pubmed: 1391987
Psychooncology. 2015 Aug;24(8):878-84
pubmed: 25534045
Br J Cancer. 2013 Aug 20;109(4):852-8
pubmed: 23868003
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437